SEARCH

SEARCH BY CITATION

References

  • 1
    Gagel RF, Cote GJ, Martins Bugalho MJC, Boyd Iii AE, Cummings T, Goepfert H, et al. Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A. J Intern Med 1995; 238: 333 41.
  • 2
    Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, et al. Low frequency of germline mutations in the RET protooncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endo 1995; 43: 123 27.
  • 3
    Saad RK, Ordonez MG, Rashid RK, Guido JJ, Hill Cs Jr, Hickey RC, Samaan NA. Medullary carcinoma of the thyroid: a study of the clinical features and prognostic factors in 161 patients. Medicine 1984; 63: 319 42.
  • 4
    Ledger GA, Khosla S, Lindor NM, Thibodeau SN, Gharib H. Genetic testing in the diagnosis and management of multiple endocrine neoplasia type 2. Ann Intern Med 1995; 122: 118 24.
  • 5
    Schuffenecker I, Billaud M, Calender A, Chambe B, Ginet N, Calmettes C, et al. RET protooncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet 1994; 3 (11): 1939 43.
  • 6
    Ponder BAJ, Ponder MA, Coffey R, Pembrey ME, Gagel RF, Telenius-Berg M, et al. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1988; i(8582): 397 401.
  • 7
    Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, et al. Mutations in the RET protooncogene are associated with MEN2A and FMTC. Hum Mol Genet 1993; 2: 851 56.
  • 8
    Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E, et al. Specific mutations of the RET protooncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genet 1994; 6: 70 4.
  • 9
    Tsai MS, Ledger GA, Khosla S, Gharib H, Thibodeau SN. Identification of multiple endocrine neoplasia type 2 gene carriers using linkage analysis and analysis of the RET protooncogene. J Clin Endocrinol Metab 1994; 78:1261 64.
  • 10
    Xue T, Yu H, Maurer LH, Memoli VA, Nutile-McMenemy N, Schuster MK, et al. Germline RET mutations in MEN 2A and FMTC and their detection by simple DNA diagnostic tests. Hum Mol Genet 1994; 3 (4): 635 38.
  • 11
    Blaugrund JE, Johns Mm Jr, Eby YJ, Ball DW, Baylin SB, Hruban RH, Sidransky D. RET protooncogene mutations in inherited and sporadic medullary thyroid cancer. Hum Mol Genet 1994; 3 (10): 1895 97.
  • 12
    Marsh DJ, Robinson BG, Andrew S, Richardson AL, Pojer R, Schnitzler M, et al. A rapid screening method for the detection of Mutations in the RET Protoonocogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families. Genomics 1994; 23: 477 79.
  • 13
    Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, et al. A novel point mutation in the tyrosine kinase domain of the RET protooncogen in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995; 10 (3): 509 13.
  • 14
    Komminoth P, Kunz EK, Matias-Guiu X, Hiort O, Christiansen G, Colomer A, et al. Analysis of RET Protooncogene point mutations distinguishes heritable from non-heritable medullary thyroid carcinomas. Cancer 1995; 76: 479 89.
  • 15
    Frank-Raue K, Hoppner W, Frilling A, Kotzerke J, Dralle H, Haase R, et al. Mutations of the RET protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. J Clin Endocrinol Metab 1996; 81: 1780 83.
  • 16
    Fink M, Weinhusel A, Niederle B, Haas OA. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET protooncogene. Study Group Multiple Endocrine Neoplasia Austria (SMENA). Int J Cancer 1996; 69 (4): 312 16.
  • 17
    Eng C, Clayton D, Schuffenecker I, Lenoir G, Gilbert C, Gagel RF, et al. The relationship between specific RET protooncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium Analysis. JAMA 1996; 276 (19): 1575 79.